Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines.
The purpose of this study is to examine the in vitro modulatory effect of tigecycline on staphylococcal superantigen-induced T-cell activation and cytokines and chemokines production by human peripheral blood mononuclear cells (PBMC). Isolated human PBMC from ten healthy volunteers were stimulated by staphylococcal enterotoxin B (SEB) and Staphylococcal toxic shock syndrome toxin-1 (TSST-1) superantigens with varying concentrations of tigecycline. Cytokines IL-1 beta, IL-6, TNF-alpha, and chemokines MIP-1 alpha and MIP-1 beta concentrations were measured along with T cell proliferation. Results demonstrated that tigecycline alters cytokine production and reduces T-cell proliferation in vitro suggesting an immunomodulatory activity independent of its antimicrobial effect.
Saliba
Ranime
R
The Veterans Affairs Western New York Healthcare System, Department of Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, New York 14215-1199, USA.
Paasch
Linda
L
El Solh
Ali
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001427:Bacterial Toxins / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D018925:Chemokines / Q000096:biosynthesis*; D016207:Cytokines / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004768:Enterotoxins / Q000494:pharmacology*; D006801:Humans; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D018089:Superantigens / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D000078304:Tigecycline; D015854:Up-Regulation / Q000276:immunology*
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D018925:Chemokines; D016207:Cytokines; D004768:Enterotoxins; D018089:Superantigens; C030107:enterotoxin F, Staphylococcal; C031818:enterotoxin B, staphylococcal; D000078304:Tigecycline; D008911:Minocycline